39 results about "Hla restriction" patented technology

The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, neutrophil elastase peptides other than PR1, cyclin E1 peptides, cyclin D peptides, or cyclin E2 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack tumor cells.

The invention relates to a method for quantitatively identifying relevant HLA-bound peptide antigens from primary tissue specimens on a large scale without labeling approaches. This method can not only be used for the development of peptide vaccines, but is also highly valuable for a molecularly defined immunomonitoring and the identification of new antigens for any immunotherapeutic strategy in which HLA-restricted antigenic determinants function as targets, such as a variety of subunit vaccines or adoptive T-cell transfer approaches in cancer, or infectious and autoimmune diseases.

The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of the target protein cells.

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

The invention relates to a reagent kit for diagnosing enzyme linked immune spots infected by tubercle bacillus and a method for preparing a specific antigen. The reagent kit comprises a reagent kit body and a detection reagent arranged in the kit body; the detection reagent comprises a positive standard solution, a chromogenic agent, a concentrated detergent and a diluent; the detection reagent also comprises a specific antigen of mycobacterium tuberculosis, a coated INF-gamma resistant antibody and an enzyme label secondary antibody of a vector protein conjugate; the specific antigen of mycobacterium tuberculosis is fusion protein expressed by an ESAT-6 gene and an EIS gene of the mycobacterium tuberculosis; and the INF-gamma resistant antibody is a murine IgG antibody. The method for preparing the specific antigen comprises the following steps: proper tubercle bacillus special antigen ESAT-6 and EIS are combined; and the prepared recombining fusion protein contains main antigenic determinants of two antigens. The recombining fusion protein definitely contains a T cell epitope suitable for the limitation of different HLA, and does not influence results by different groups and different HLA distribution. Clinical tests on tuberculosis patients and healthy people of different groups show that the reagent kit has more excellent specificity and sensitivity than a current similar product.

The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as immunogenic compositions for treating and/or preventing breast cancer in an individual. In specific aspects, PR1 peptide or a derivative thereof, or a myeloperoxidase peptide, or a cyclin E1 or E2 peptide is provided in methods and compositions for breast cancer treatment and/or prevention. Such peptides can be used to elicit specific CTLs that preferentially attack breast cancer based on overexpression of the target protein cells.

An antibody capable of binding, with a human major histocompatibility complex (MHC)-restricted specificity, a MHC being complexed with an HLA-restricted peptide antigen is provided. The antibody having a binding specificity dictated by at least 4 amino acid residues in said HLA-restricted peptide such that at least 70% reduction in binding of said antibody to said complex is observed when each of said at least 4 amino acid residues is substituted as determined by FACS of cells loaded with said HLA-restricted peptide comprising said substitution, said at least 4 amino acid residues not being anchor residues.

The invention relates to Helicobacter pylori antigen HLA restrictive immunodominance epitope peptide as well as a preparation method and application thereof. The dominance epitope peptide has the amino acid sequences shown in SEQ ID NO:63, 74, 95 and 105. The invention also provides a preparation method of the epitope peptide, and further provides application of the epitope peptide to preparation for preventing or treating Helicobacter pylori infection.

The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X₁=a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X₂=a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

The present invention provides an avian influenza vaccine containing a peptide-bound liposome wherein;

• the peptide contains:
• (1) an amino acid sequence shown by any one of SEQ ID NO:1 to 9, or
• (2) an amino acid sequence shown by any one of SEQ ID NO:1 to 9 wherein one or two amino acids are substituted,
• has a length of 9 to 11 amino acids, and
• is capable of inducing HLA-restricted cytotoxic T lymphocytes; wherein the liposome contains a phospholipid having an acyl group with 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group with 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer; and wherein the peptide is bound to the surface of the liposome.

In an attempt to improve primary disease responsiveness and/or to overcome resistant disease, the present disclosure provides a method for treating or inhibiting the proliferation of a WT-1 -dependent cancer comprising providing to a subject in need thereof a therapeutically effective amount of a tyrosine kinase inhibitor along with an anti-WT-1 /HLA antibody, that is, an antibody that specifically binds to a peptide of Wilms' tumor protein (WT-1 ) presented on the surface of the cancer cells in an HLA-restricted fashion.

The present invention describes ways to identify HLA allele-specific epitopes that result from HLA restriction of antigen-specific cellular immune responses. The invention employs a combination of bioinformatics and functional assays to systematically identify and classify CTL mutations to determine correlates of virus-host interactions Peptides representing HLA allele-specific epitopes are provided as well as methods for validating HLA-restricted epitopes and methods for measuring T cell responses.